open access Frontiers | Epigenomics of Ovarian Cancer and Its Chemoprevention | Frontiers in Epigenomics

.......Due to the atypical syndrome of the early stage of ovarian cancer, it is difficult to diagnose in its early stages. By the time most ovarian cancers are diagnosed, they are already at stage III or IV. The two most significant obstacles to the effective treatment of ovarian cancers are the lack of early diagnostic markers and the development of drug resistance after therapeutic treatment of advanced disease. Ovarian cancer screening with transvaginal ultrasound (TVU) and CA125 was evaluated in the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial, however, it was revealed that the predictive value of both tests was relatively low (Buys et al., 2005). Increasing evidence indicates that epigenetic mechanisms may play a major role in the development of ovarian cancer..........
In this analysis, we will evaluate the current status of epigenomics of ovarian cancer and will include epigenetic mechanisms involved in ovarian cancer development such as DNA methylation, histone modifications, and non-coding microRNA. Development of biomarkers, the epigenetic basis for drug resistance and improved chemotherapy for ovarian cancer will also be assessed. In addition, the potential use of natural compounds as epigenetic modulators in chemotherapy shows promise in moving to the forefront of ovarian cancer treatment strategies........

Cancer epigenomics: Implications of DNA methylation in personalized cancer therapy - Cancer Science

Note: in research; see Table 1 for references to ovarian cancer/cisplatin

"Methylation of FANCF has been found in 20% of primary ovarian cancers not previously exposed to cisplatin, but the correlation between chemosensitivity and FANCF methylation in primary tumors remains to be determined."

(full free access) Foreword: Today’s discoveries to tomorrow’s care: cancer biomarkers revisited

1) link:  Themed content: Using biomarkers to individualize and monitor cancer therapy - Foreword

2) link: Epigenomics and ovarian carcinoma

Leonel Maldonado, Mohammad Obaidul Hoque

Biomarkers in Medicine, August 2010, Vol. 4, No. 4, Pages 543-570.

(Summary)

 

.